Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention

详细信息    查看全文

• 作者：Lyudmila A. Garbovsky ; Byron C. Drumheller…
• 关键词：Phenytoin ; Adverse drug events ; Purple glove syndrome ; Fosphenytoin ; Hand injuries ; Forearm injuries ; Vascular injuries ; Emergency services
• 刊名：Journal of Medical Toxicology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：11
• 期：4
• 页码：445-459
• 全文大小：1,177 KB
• 参考文献：1.Parenteral Dilantin (Phenytoin Sodium Injection, USP) [prescribing information]. Revised February 2013. Parke Davis: New York. http://鈥媤ww.鈥媋ccessdata.鈥媐da.鈥媑ov/鈥媎rugsatfda_鈥媎ocs/鈥媗abel/鈥?013/鈥?10151s037lbl.鈥媝df . Accessed 6 June 2015.
  2.Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348鈥?5.CrossRef PubMed
  3.Cerebyx (Fosphenytoin Sodium Injection) [prescribing information]. Pfizer Labs: New York. Revised April 2014. http://鈥媗abeling.鈥媝fizer.鈥媍om/鈥婼howLabeling.鈥媋spx?鈥媔d=鈥?49 . Accessed 6 June 2015.
  4.Comer J. Extravasation from intravenous phenytoin. Am J Intraven Ther Clin Nutr. 1984;11:23鈥?.
  5.Hanna D. Purple glove syndrome: a complication of intravenous phenytoin. J Neurosci Nurs. 1992;24(6):340鈥?.CrossRef PubMed
  6.Intravenous Phenytoin and Fosphenytoin Safety Concerns Background Package. Available at: http://鈥媤ww.鈥媐da.鈥媑ov/鈥媎ownloads/鈥媋dvisorycommitte鈥媏s/鈥媍ommitteesmeetin鈥媑materials/鈥媎rugs/鈥媝eripheralandcen鈥媡ralnervoussyste鈥媘drugsadvisoryco鈥媘mittee/鈥媢cm231776.鈥媝df . Accessed 6 June 2015.
  7.Brophy G, Bell R, Claassen J, Alldredge B, Bleck T, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3鈥?3.CrossRef PubMed
  8.Huff J, Melnick E, Tomaszewski C, Thiessen M, Jagoda A, Fesmire F. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med. 2014;63(4):437鈥?47.e15.CrossRef PubMed
  9.Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, et al. Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma. 2007;24 Suppl 1:S83鈥?.
  10.Shorvon S, Baulac M, Cross H, Trinka E, Walker M, et al. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London colloquium on status epilepticus. Epilepsia. 2008;49(7):1277鈥?5.PubMed
  11.Birbeck GL, French JA, Perucca E, Simpson DM, Fraimov H, George JM, et al. Evidence-based guidelins: antiepileptic drug selection for people with HIV/AIDS: report of the quality standards subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78(2):139鈥?5.PubMedCentral CrossRef PubMed
  12.Summary of information about Purple Glove Syndrome in association with intravenous administration of phenytoin and fosphenytoin. Available at: http://鈥媤ww.鈥媐da.鈥媑ov/鈥媎ownloads/鈥婣dvisoryCommitte鈥媏s/鈥婥ommitteesMeetin鈥媑Materials/鈥婦rugs/鈥婸eripheralandCen鈥媡ralNervousSyste鈥媘DrugsAdvisoryCo鈥媘mittee/鈥婾CM231777.鈥媝df . Accessed 6 June 2015.
  13.Chhabra P, Gupta N, Kaushik A. Compartment syndrome as a spectrum of purple glove syndrome following intravenous phenytoin administration in a young male: a case report and review of literature. Neurol India. 2013;61(4):419鈥?0.CrossRef PubMed
  14.Jain RS, Nagpal K, Kumar S, Prakash S, Handa R. Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma. Am J Emerg Med. 2015;33(1):123.e5鈥?.CrossRef
  15.Helfaer M, Ware C. Purple glove syndrome. J Neurosurg Anesthesiol. 1994;6(1):48鈥?.CrossRef PubMed
  16.Sharief N, Goonasekera C. Soft tissue injury associated with intravenous phenytoin in a neonate. Acta Paediatr. 1994;83(11):1218鈥?.CrossRef PubMed
  17.Bhattacharjee P, Glusac E. Early histopathologic changes in purple glove syndrome. J Cutan Pathol. 2004;31(7):513鈥?.CrossRef PubMed
  18.Santoshi J, Justin A, Jacob J, Pallapati S, Thomas B. Purple glove syndrome: a case report. Hand surgeons and physicians be aware. J Plast Reconstr Aesthet Surg: JPRAS. 2010;63(3):e340鈥?.CrossRef PubMed
  19.Sonohata M, Asami A, Tsunoda K, Hotokebuchi T. Purple glove syndrome associated with intravenous phenytoin administration in a patient with severe mental and motor retardation. J Orthop Sci. 2006;11(4):409鈥?1.CrossRef PubMed
  20.Hayes A, Chesney T. Necrosis of the hand after extravasation of intravenously administered phenytoin. J Am Acad Dermatol. 1993;28(6):360鈥?.CrossRef PubMed
  21.Hunt S. Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Am J Dermatopathol. 1995;17(4):399鈥?02.PubMed
  22.O鈥橞rien T, Cascino G, So E, Hanna D. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology. 1998;51(4):1034鈥?.CrossRef PubMed
  23.Spengler R, Arrowsmith J, Kilarski D, Buchanan C, Von Behren L, Graham D. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch Intern Med. 1988;148(6):1329鈥?3.CrossRef PubMed
  24.Jamerson B, Dukes G, Brouwer K, Donn K, Messenheimer J, Powell J. Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacother: J Hum Pharmacol Drug Ther. 1994;14(1):47鈥?2.
  25.Doellman D, Hadaway L, Bowe-Geddes L, Franklin M, LeDonne J, Parke-O鈥橠onnell L, et al. Infiltration and extravasation. Update on prevention and management. J Infus Nurs. 2009;32(4):203鈥?1.CrossRef PubMed
  26.Hannon M, Lee S. Extravasation injuries. J Hand Surg. 2011;36A:2060鈥?.CrossRef
  27.Sokol D, Dahlmann A, Dunn D. Hyaluronidase treatment for intravenous phenytoin extravasation. J Child Neurol. 1998;13(5):246鈥?.CrossRef PubMed
  28.Prince N, Hill C. Purple glove syndrome following intravenous phenytoin administration. Arch Dis Child. 2011;96(8):734.CrossRef PubMed
  29.Prasad R, Mishra O, Gupta A. Gangrene of left hand following accidental intra-arterial injection of phenytoin sodium. Pediatric Oncall [serial online] 2012. doi: 10.鈥?199/鈥媝ed.鈥媜ncall.鈥?012.鈥?8 .
  30.Sintenie J, Tuinebreijer W, Kreis R, Breederveld R. Digital gangrene after accidental intra-arterial injection of phenytoin (Epanutin). Eur J Surg. 1992;158(5):315鈥?.PubMed
  31.Mahajan R, Batra Y, Rajeev S. Intravenous phenytoin and percutaneous arterial cannulation: the purple-glove syndrome. Eur J Anaesthesiol. 2007;24(10):900鈥?.CrossRef PubMed
  32.Edwards J, Bosek V. Extravasation injury of the upper extremity by intravenous phenytoin. Anesth Analg. 2002;94(3):672鈥?.CrossRef PubMed
  33.Hagan 3rd H, Hastings H. Extravasation of phenytoin in the hand. J Hand Surg - Am. 1988;13(6):942鈥?.CrossRef PubMed
  34.Snelson C, Dieckman B. Recognizing and managing purple glove syndrome. Crit Care Nurse. 2000;20(3):54鈥?1.PubMed
  35.Singh G, Cherian V, Thomas B. Low-concentration, continuous brachial plexus block in the management of purple glove syndrome: a case report. J Med Case Rep. 2010. doi:10.鈥?186/鈥?752-1947-4-48 .
  36.Twardowschy C, De Paola L, Germiniani F, Werneck LC, Silvado C. Pearls & oy-sters: soft-tissue necrosis as a result of intravenous leakage of phenytoin. Neurology. 2009;73(19):e94鈥?.CrossRef PubMed
  37.Chokshi R, Openshaw J, Mehta N, Mohler 3rd E. Purple glove syndrome following intravenous phenytoin administration. Vasc Med. 2007;12(1):29鈥?1.CrossRef PubMed
  38.Senthilkumaran S, Balamurgan N, Suresh P, Phirumalaikolundusubramanian P. Purple glove syndrome: a looming threat. J Neurosci Rural Pract. 2010;1(2):121鈥?.PubMedCentral CrossRef PubMed
  39.Lalla R, Malhotra H, Garg R, Sahu R. Purple glove syndrome: a dreadful complication of intravenous phenytoin administration. BMJ Case Rep. 2012. doi:10.鈥?136/鈥媌cr-2012-006653 .
  40.Burneo J, Anandan J, Barkley G. A prospective study of the incidence of the purple glove syndrome. Epilepsia. 2001;42(9):1156鈥?.CrossRef PubMed
  41.Grinder D, Guastella CP, Pellegrino M. Soft-tissue damage and intravenous phenytoin. Drug Intell Clin Pharm. 1988;22(9):725鈥?.PubMed
  42.Fishel M, Sauer S, Allen J. When you give phenytoin i.v. RN. 1990;53(9):58鈥?.PubMed
  43.Cadenbach A, Rottger K, Muller M. 鈥淧urple glove syndrome.鈥?Severe soft tissue reaction following phenytoin infusion. Dtsch Med Wochenschr. 1998;123(11):318鈥?2.CrossRef PubMed
  44.Scumpia A, Yahsou J, Cajina J, Cao C. Purple glove syndrome after intravenous phenytoin administration presenting in the emergency department. J Emerg Med. 2013;44(2):e281鈥?.CrossRef PubMed
  45.McLean C, Cheng K, Clifton M. Fatal case of accidental intra-arterial phenytoin injection. Eur J Vasc Endovasc Surg. 2002;23(4):378鈥?.CrossRef PubMed
  46.Rao V, Feldman P, Dibbell D. Extravasation injury to the hand by intravenous phenytoin. Report of three cases. J Neurosurg. 1988;68(6):967鈥?.CrossRef PubMed
  47.Kasdan M, June L. Extravasation of phenytoin and diazepam requiring surgical debridement and skin grafting. Orthopedics. 1993;16(12):1355鈥?.PubMed
  48.Marders J. Sounding the alarm for I.V. infiltration. Nursing. 2005;35(4):18鈥?0.CrossRef PubMed
  49.Weinstein M. Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med. 1989;149(8):1905.CrossRef PubMed
  50.Keane M, Shirazi H, Marsh P, Khushal A. Purple glove syndrome following intravenous phenytoin infusion. Br J Surg. 2009;96(9):1065.
  51.Kirsch S, Bayard M, Darraj K. Distal upper extremity edema and discoloration. Am Fam Physician. 2007;75(6):889鈥?1.PubMed
  52.Rajabally H, Nageshwaran S, Russell S. An atypical case of purple glove syndrome: an avoidable adverse event. BMJ Case Reports. 2012. doi:10.鈥?136/鈥媌cr.鈥?1.鈥?012.鈥?653 .PubMedCentral PubMed
  53.Kilarski D, Buchanan C, Von Behren L. Soft-tissue damage associated with intravenous phenytoin. N Engl J Med. 1984;311(18):1186鈥?.PubMed
  54.McDonnell P. Purple glove syndrome. PA PSRS Patient Saf Advis. 2006;3(4):12鈥?. Available at: http://鈥媝atientsafetyaut鈥媓ority.鈥媜rg/鈥婣DVISORIES/鈥婣dvisoryLibrary/鈥?006/鈥婦ec3%284%29/鈥媎ocuments/鈥?2.鈥媝df . Accessed 6 June 2015.
  55.Earnest M, Marx J, Drury L. Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA. 1983;249(6):762鈥?.CrossRef PubMed
  56.Phenytoin sodium injection, USP [prescribing information]. Hospira Inc: Lake Forrest. Revised November 2010. http://鈥媤ww.鈥媓ospira.鈥媍om/鈥婭mages/鈥婨N-2681_鈥?1-5775_鈥?.鈥媝df . Accessed 6 June 2015.
  57.Phenytoin Sodium Injection, USP [prescribing information]. West-Ward Pharmaceutical Corps: Eatontown. Revised April 2015. http://鈥媎ailymed.鈥媙lm.鈥媙ih.鈥媑ov/鈥媎ailymed/鈥媎rugInfo.鈥媍fm?鈥媠etid=鈥?35a8d4e-2063-4240-83cb-d7eebcabe301 . Accessed 6 June 2015.
  58.Phenytoin sodium injection, USP [prescribing information]. X-Gen Pharmaceuticals. Big Flats: NY. Revised February 2011. http://鈥媥-gen.鈥媢s/鈥媤p-content/鈥媢ploads/鈥?014/鈥?3/鈥媝henytoin_鈥媝i.鈥媝df . Accessed 6 June 2015.
  59.Beaulieu M. Hyaluronidase for extravasation management. Neonatal Netw - J Neonatal Nurs. 2012;31(6):413鈥?.CrossRef
  60.Inaba K, Menaker J, Branco B, Gooch J, Okoye O, Herrold J, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg. 2013;74(3):766鈥?1.CrossRef PubMed
  61.Yoshikawa H, Abe T, Oda Y. Purple glove syndrome caused by oral administration of phenytoin. J Child Neurol. 2000;15(11):762.CrossRef PubMed
  
• 作者单位：Lyudmila A. Garbovsky (1)
  Byron C. Drumheller (3)
  Jeanmarie Perrone (2) (3)
  
  1. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  3. Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
  2. Division of Medical Toxicology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  
• 刊物主题：Pharmacology/Toxicology; Biomedicine general;
• 出版者：Springer US
• ISSN：1937-6995

文摘

The aim of our study was to identify all previously reported cases of phenytoin- or fosphenytoin-associated purple glove syndrome (PGS) and summarize the most current understanding of the pathophysiology, clinical presentation, diagnosis, and treatment of the disease. We searched the English language references from MEDLINE, EMBASE, CINAHL, TOXNET, and gray literature that featured one or more case descriptions of phenytoin- or fosphenytoin-associated PGS after administration and provided information on the clinical setting of the event and associated outcome(s). Descriptive statistics were employed to summarize relevant facts about the cases. We identified 82 unique cases of parenteral phenytoin-associated PGS and 5 cases of fosphenytoin-associated PGS that were published from 1984 to 2015. Additionally, we found two cases of PGS associated with oral formulation of phenytoin published from 1999 to 2015. The spectrum of tissue injury ranged from mild local cutaneous reactions around the infusion site to frank limb ischemia. Just over a half of cases reported symptoms after one dose of IV phenytoin. Pathologic findings included evidence for microvascular thrombosis and possible microvascular or subclinical extravasation as a contributing mechanism. Dopper ultrasound and conventional angiography were used in some patients to identify arterial or venous thrombosis. Various treatments were documented including the use of supportive care such as limb elevation and heat or cold application, utilization of systemic antibiotics, anticoagulants, or vasodilators, and local infiltration of hyaluronidase, heparin, or other compounds. In a small number of patients, invasive interventions such as regional anesthesia, thrombectomy, fasciotomy, and debridement were described. Time to resolution varied from days to weeks. Resolution of PGS without deficits was documented in the majority of cases. Skin changes followed by sensory and motor deficits were described in 16, 6, and 5 cases, respectively. Four patients underwent skin grafting and eight patients required limb amputation. Death as a result of PGS was documented in two patients. PGS associated with oral and injectable phenytoin or parenteral fosphenytoin has been documented in the literature and sometimes includes significant vascular thrombosis and potentially limb-threatening ischemia. Avoidance of small hand veins, adherence to recommended IV administration guidelines and monitoring of the infusion site for reactions should be considered to decrease the morbidity of IV phenytoin or fosphenytoin use. Patients with PGS and evidence of decreased distal perfusion should undergo prompt vascular imaging and potential intervention to avoid ischemic sequelae. Alternative anticonvulsant drugs should be considered in patients at risk for PGS when possible. Keywords Phenytoin Adverse drug events Purple glove syndrome Fosphenytoin Hand injuries Forearm injuries Vascular injuries Emergency services